Genmab A/S

Copenhagen Stock Exchange GMAB.CO

Genmab A/S Net Income Margin for the year ending December 31, 2023: 26.42%

Genmab A/S Net Income Margin is 26.42% for the year ending December 31, 2023, a -29.28% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Genmab A/S Net Income Margin for the year ending December 31, 2022 was 37.36%, a 7.15% change year over year.
Genmab A/S Net Income Margin for the year ending December 31, 2021 was 34.86%, a -25.92% change year over year.
Genmab A/S Net Income Margin for the year ending December 31, 2020 was 47.06%, a 16.58% change year over year.
Genmab A/S Net Income Margin for the year ending December 31, 2019 was 40.37%, a -17.05% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Copenhagen Stock Exchange: GMAB.CO

Genmab A/S

CEO	Dr. Jan G.J. van de Winkel Ph.D.
IPO Date	Oct. 20, 2000
Location	Denmark
Headquarters	Kalvebod Brygge 43
Employees	2,635
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years